About MIMETAS
Every year, drugs fail in late-stage trials because traditional models can’t accurately predict how they’ll function in humans. At MIMETAS, we’re changing that.
We create the world’s most advanced human tissue and disease models using our organ-on-a-chip technology – enabling faster development of safer and more effective therapies that improve patient lives.
Our Mission & Vision
Our mission is to develop the world’s most advanced in vitro models to support the creation of breakthrough medicines for today’s unmet medical needs.
We envision a future where every new medicine is developed and tested using advanced 3D human tissue and disease models – accelerating innovation, lowering costs, and saving lives.
From Innovation to
Industry Standard
Founded in 2013 in Leiden, the Netherlands, and Gaithersburg, Maryland, USA, MIMETAS has been at the forefront of organ-on-a-chip innovation.
With the launch of OrganoPlate® – the world’s first mass-produced, quality-controlled organ-on-a-chip platform – we set a new benchmark for physiologically relevant cell culture, while keeping the usability and throughput scientists expect from traditional methods.
MIMETAS in Numbers
80+ Employees
4 offices in the Netherlands, USA, and Japan
130+ peer-reviewed publications
200+ successful projects
4.8/5 customer satisfaction
Our People
MIMETAS brings together a passionate, cross-continental team of scientists, engineers, and innovators working at the forefront of human biology.
From the United States to Europe and Asia, our teams partner closely with clients to solve problems at the cutting edge of disease understanding and drug discovery.
Leadership
and Co-Founder
and Co-Founder
.avif)
.avif)
The I in Mimetas
We’re Hiring!
Browse our open vacancies and become the next I in MIMETAS!
Work With Us
Ready to accelerate your research with the most advanced human-relevant models?